Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.3K
Coagulation01:09

Coagulation

9.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.

Science translational medicine·2026
Same author

Adoptive T-cell therapies in the clinic.

Bioengineering & translational medicine·2026
Same author

RNAs anchoring replication complex control initiation and firing of DNA replication.

Nature communications·2026
Same author

Closure of an urban level 1 trauma center and firearm assault mortality: The death of Hahnemann University Hospital.

Surgery·2026
Same author

In-the-Clinic series: A 10 year journey.

Bioengineering & translational medicine·2026
Same author

Lyophilized Synthetic Platelets: In Vitro Characterization and in Vivo Evaluation in Mouse Thrombocytopenia Model.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Erratum for the Research Article "Assessing the health risks of rice cadmium content standards in China" by H. Chu <i>et al</i>.

Science advances·2026
Same journal

Erratum for the Research Article "Developmental regulation of Erk signaling by mitotic kinases" by F. Chen <i>et al</i>.

Science advances·2026
Same journal

Magnetically levitated metasurface enabling tangible and bidirectional human-machine interaction.

Science advances·2026
Same journal

A general photoinduced manganese-catalyzed platform for the sequential difunctionalization of [1.1.1]propellane.

Science advances·2026
Same journal

Turning sound and force into light with AlN:Mn<sup>2+</sup> mechanoluminescence.

Science advances·2026
Same journal

Extreme dominance of Earth-origin heavy ions in the intense ring current near the Earth during the May 2024 super geomagnetic storm.

Science advances·2026
See all related articles

Related Experiment Video

Updated: Dec 12, 2025

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
08:40

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application

Published on: June 8, 2016

14.5K

A polymer-based systemic hemostatic agent.

Yongsheng Gao1, Apoorva Sarode1, Nikolaos Kokoroskos2

  • 1John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.

Science Advances
|August 11, 2020
PubMed
Summary
This summary is machine-generated.

A new injectable hemostat, HAPPI (Hyaluronic acid-based polymer peptide interfusion), effectively stops severe bleeding. This novel agent shows significant improvements in survival time and blood loss reduction in preclinical models.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

7.9K

Related Experiment Videos

Last Updated: Dec 12, 2025

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
08:40

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application

Published on: June 8, 2016

14.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

7.9K

Area of Science:

  • Biomaterials Science
  • Hemostasis
  • Trauma Medicine

Background:

  • Uncontrolled noncompressible hemorrhage is a leading cause of death in trauma patients.
  • There is a critical need for effective point-of-care injectable hemostatic agents.

Purpose of the Study:

  • To develop and evaluate an injectable hemostatic agent, HAPPI, for treating severe bleeding.
  • To assess HAPPI's efficacy in preclinical models of traumatic injury.

Main Methods:

  • HAPPI was synthesized as a hyaluronic acid conjugate with collagen-binding and von Willebrand factor-binding peptides.
  • In vitro studies assessed HAPPI's interaction with activated platelets.
  • In vivo efficacy was evaluated in mouse tail vein laceration and rat inferior vena cava injury models.

Main Results:

  • HAPPI selectively bound activated platelets and promoted their aggregation in vitro.
  • HAPPI reduced bleeding time and blood loss by over 97% in a mouse model.
  • A 284% improvement in survival time was observed in a rat model of severe hemorrhage.

Conclusions:

  • HAPPI is a novel injectable hemostatic agent with significant potential for clinical translation.
  • Lyophilized HAPPI demonstrates long-term stability at room temperature, facilitating storage and use.
  • HAPPI offers a promising solution for managing life-threatening hemorrhage at the point of care.